These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
815 related articles for article (PubMed ID: 33316346)
1. Vaccine formulations in clinical development for the prevention of severe acute respiratory syndrome coronavirus 2 infection. Batty CJ; Heise MT; Bachelder EM; Ainslie KM Adv Drug Deliv Rev; 2021 Feb; 169():168-189. PubMed ID: 33316346 [TBL] [Abstract][Full Text] [Related]
5. SARS-CoV-2 vaccine development: where are we? Galdiero M; Galdiero M; Folliero V; Zannella C; De Filippis A; Mali A; Rinaldi L; Franci G Eur Rev Med Pharmacol Sci; 2021 Mar; 25(6):2752-2784. PubMed ID: 33829462 [TBL] [Abstract][Full Text] [Related]
6. The 2020 race towards SARS-CoV-2 specific vaccines. Karpiński TM; Ożarowski M; Seremak-Mrozikiewicz A; Wolski H; Wlodkowic D Theranostics; 2021; 11(4):1690-1702. PubMed ID: 33408775 [TBL] [Abstract][Full Text] [Related]
7. SARS-CoV-2 vaccine candidates in rapid development. Li L; Guo P; Zhang X; Yu Z; Zhang W; Sun H Hum Vaccin Immunother; 2021 Mar; 17(3):644-653. PubMed ID: 33121319 [TBL] [Abstract][Full Text] [Related]
8. A Review of the Progress and Challenges of Developing a Vaccine for COVID-19. Sharma O; Sultan AA; Ding H; Triggle CR Front Immunol; 2020; 11():585354. PubMed ID: 33163000 [TBL] [Abstract][Full Text] [Related]
9. Severe acute respiratory syndrome-coronavirus-2 spike (S) protein based vaccine candidates: State of the art and future prospects. Arashkia A; Jalilvand S; Mohajel N; Afchangi A; Azadmanesh K; Salehi-Vaziri M; Fazlalipour M; Pouriayevali MH; Jalali T; Mousavi Nasab SD; Roohvand F; Shoja Z; Rev Med Virol; 2021 May; 31(3):e2183. PubMed ID: 33594794 [TBL] [Abstract][Full Text] [Related]
10. Recombinant protein vaccines, a proven approach against coronavirus pandemics. Pollet J; Chen WH; Strych U Adv Drug Deliv Rev; 2021 Mar; 170():71-82. PubMed ID: 33421475 [TBL] [Abstract][Full Text] [Related]
11. New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates. Ura T; Yamashita A; Mizuki N; Okuda K; Shimada M Vaccine; 2021 Jan; 39(2):197-201. PubMed ID: 33279318 [TBL] [Abstract][Full Text] [Related]
12. A Methyltransferase-Defective Vesicular Stomatitis Virus-Based SARS-CoV-2 Vaccine Candidate Provides Complete Protection against SARS-CoV-2 Infection in Hamsters. Lu M; Zhang Y; Dravid P; Li A; Zeng C; Kc M; Trivedi S; Sharma H; Chaiwatpongsakorn S; Zani A; Kenney A; Cai C; Ye C; Liang X; Qiu J; Martinez-Sobrido L; Yount JS; Boyaka PN; Liu SL; Peeples ME; Kapoor A; Li J J Virol; 2021 Sep; 95(20):e0059221. PubMed ID: 34379509 [TBL] [Abstract][Full Text] [Related]
13. COVID-19 vaccine development during pandemic: gap analysis, opportunities, and impact on future emerging infectious disease development strategies. Rele S Hum Vaccin Immunother; 2021 Apr; 17(4):1122-1127. PubMed ID: 32993453 [TBL] [Abstract][Full Text] [Related]
14. SARS-CoV-2: Targeted managements and vaccine development. Bakhiet M; Taurin S Cytokine Growth Factor Rev; 2021 Apr; 58():16-29. PubMed ID: 33293238 [TBL] [Abstract][Full Text] [Related]
15. Coronavirus Disease (COVID-19): Current Status and Prospects for Drug and Vaccine Development. Ita K Arch Med Res; 2021 Jan; 52(1):15-24. PubMed ID: 32950264 [TBL] [Abstract][Full Text] [Related]
16. Advances in gene-based vaccine platforms to address the COVID-19 pandemic. Pushparajah D; Jimenez S; Wong S; Alattas H; Nafissi N; Slavcev RA Adv Drug Deliv Rev; 2021 Mar; 170():113-141. PubMed ID: 33422546 [TBL] [Abstract][Full Text] [Related]
17. Potential adjuvants for the development of a SARS-CoV-2 vaccine based on experimental results from similar coronaviruses. Gupta T; Gupta SK Int Immunopharmacol; 2020 Sep; 86():106717. PubMed ID: 32585611 [TBL] [Abstract][Full Text] [Related]
18. A Perspective on the Roles of Adjuvants in Developing Highly Potent COVID-19 Vaccines. Zhang N; Li K; Liu Z; Nandakumar KS; Jiang S Viruses; 2022 Feb; 14(2):. PubMed ID: 35215980 [TBL] [Abstract][Full Text] [Related]
19. Sterilizing Immunity against SARS-CoV-2 Infection in Mice by a Single-Shot and Lipid Amphiphile Imidazoquinoline TLR7/8 Agonist-Adjuvanted Recombinant Spike Protein Vaccine*. Jangra S; De Vrieze J; Choi A; Rathnasinghe R; Laghlali G; Uvyn A; Van Herck S; Nuhn L; Deswarte K; Zhong Z; Sanders NN; Lienenklaus S; David SA; Strohmeier S; Amanat F; Krammer F; Hammad H; Lambrecht BN; Coughlan L; García-Sastre A; De Geest BG; Schotsaert M Angew Chem Int Ed Engl; 2021 Apr; 60(17):9467-9473. PubMed ID: 33464672 [TBL] [Abstract][Full Text] [Related]
20. Frontrunners in the race to develop a SARS-CoV-2 vaccine. Russell RL; Pelka P; Mark BL Can J Microbiol; 2021 Mar; 67(3):189-212. PubMed ID: 33264067 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]